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Introduction: The human epidermal growth factor receptor 2 (HER2) represents one of the most studied
tumor-associated antigens (TAAs) for cancer immunotherapy. The monoclonal antibody (mAb) trastuzumab has
improved the outcomes of patients with HER2+ breast cancer. However, a large number of HER2+ tumors are not
responsive to, or become resistant to, trastuzumab-based therapy, and thus more effective therapies targeting HER2
are needed.
Methods: HER2-specific T cells were generated by the transfer of genes that encode chimeric antigen receptor
(CAR). Using a multistep overlap extension PCR method, we constructed a novel, humanized HER2 CAR-containing,
chA21 single-chain variable fragment (scFv) region of antigen-specific mAb and T-cell intracellular signaling chains
made up of CD28 and CD3ζ. An interferon γ and interleukin 2 enzyme-linked immunosorbent assay and a
chromium-51 release assay were used to evaluate the antitumor immune response of CAR T cells in coculture with
tumor cells. Furthermore, SKBR3 tumor–bearing nonobese diabetic/severe combined immunodeficiency (NOD/SCID)
mice were treated with HER2 CAR T cells to evaluate antitumor activity. Human CD3+ T cell accumulation in tumor
xenograft was detected by immunohistochemistry.
Results: chA21-28z CAR was successfully constructed, and both CD4+ and CD8+ T cells were transduced. The
expanded HER2 CAR T cells expressed a central memory phenotype and specifically reacted against HER2+ tumor
cell lines. Furthermore, the SKBR3 tumor xenograft model revealed that HER2 CAR T cells significantly inhibited
tumor growth in vivo. Immunohistochemical analysis showed robust accumulation of human CD3+ T cells in
regressing SKBR3 lesions.
Conclusions: The results of this study show that novel chA21 scFv-based, HER2-specific CAR T cells not only recognized
and killed HER2+ breast and ovarian cancer cells ex vivo but also induced regression of experimental breast cancer
in vivo. Our data support further exploration of the HER2 CAR T-cell therapy for HER2-expressing cancers.Introduction
Human epidermal growth factor receptor 2 (HER2; also
called Her-2/neu or ErbB2) is a member of the trans-
membrane epidermal growth factor receptor family and
is one of the most studied tumor-associated antigens
(TAAs) for cancer immunotherapy [1]. The monoclonal
antibody (mAb) trastuzumab has improved the outcomes
of patients with breast cancer who overexpress HER2 [2].
However, a consistent number of HER2+ tumors are not
responsive to, or become resistant to, trastuzumab-based* Correspondence: sunyuping@live.cn
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unless otherwise stated.therapy, suggesting the need to develop additional novel
therapies targeting HER2 [3]. Adoptive transfer of au-
tologous tumor-reactive, tumor-infiltrating lymphocytes
(TILs) can cause regression of solid tumors [4,5]. However,
a major obstacle in the more widespread application of
TIL therapy is the difficulty in identifying antigen-
specific T cells in most human tumors [6]. Methods
have been developed to engineer peripheral blood T cells
to express a chimeric antigen receptor (CAR) [7,8]. CARs
can be constructed by attaching a single-chain variable
fragment (scFv) region of antigen-specific mAb to T-cell
intracellular signaling chains. Transducing the resultant
molecule into T cells enables these effector cells to recog-
nize targets using antigen recognition of the antibody, and
CARs are therefore major histocompatibility complex. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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antigen specificity of an antibody with the ability to kill
tumor cells mediated by T cells in a single fusion molecule
[7-9]. Furthermore, CAR-modified T cells actively and
specifically home to tumor sites and possess the capacity
to expand and persist over the long term after tumor
recognition in vivo. As such, CAR-modified T cells tar-
geted to TAAs may be more effective than mAbs in gener-
ating durable tumor responses. In addition, it has been
demonstrated that new-generation CARs containing the
costimulatory signal domain of CD28 and/or 4-1BB, or
other costimulatory molecules, enhance the function of
the gene-modified T cells [10,11].
To date, the majority of CARs studied in clinical trials
have been reconstructed with murine scFv specific for
the TAAs, which have been shown to trigger a host
immune response and thereby accelerate T-cell clearance,
which has limited their success [12,13]. Hence, CARs con-
taining both optimized costimulatory signaling domains
and humanized or fully human scFv may be best suited
for clinical trials of CAR-based T-cell therapy for cancer
patients.
In the present study, we constructed a novel humanized
anti-HER2 chA21 scFv-based CAR containing a fused
CD28/CD3ζ endodomain (designated chA21-28z CAR) to
achieve full T-cell activation. Our results show that the
chA21-28z CAR T cells specifically reacted against HER2+
tumor cells in vitro and that these T cells caused dramatic
inhibition of established HER2+ tumor cells after systemic




The human breast cancer cell lines SKBR3, MCF-7, T47D
and MDA-MB-231 and the ovarian cancer cell lines
SKOV3, OVCAR3, A2780 and A1847 were purchased
from the American Type Culture Collection (ATCC;
Manassas, VA, USA). TC-1, a human papillomavirus type
16–transformed mouse lung epithelial cell line obtained
from ATCC, was used as a negative control for human
HER2 expression. All tumor cell lines were cultured in
complete medium composed of RPMI 1640, 10% heat-
inactivated fetal bovine serum, 100 U/ml penicillin,
100 μg/ml streptomycin and 2 mM glutamine (all from
Invitrogen, Carlsbad, CA, USA). Peripheral blood mono-
nuclear cells (PBMCs) were cultured in the same medium
with the addition of 100 U/ml human recombinant inter-
leukin 2 (IL-2) (PeproTech, Suzhou, China) at 37°C and
5% CO2.
Generation of a chimeric antigen receptor construct
A PEE14-chA21 plasmid containing humanized anti-HER2
chA21 scFv, described previously [14,15], was kindlyprovided by Prof Jing Liu (School of Life Science, University
of Science and Technology of China). The CAR construct
was generated through gene splicing by multistep overlap
extension PCR (OE-PCR). The primers used are summa-
rized in Table 1. The chA21-28z CAR was constructed
based on one described in a previously published paper
[10,16]. It consisted of a human CD8a leader sequence
(amino acids 1 to 21), chA21 scFv, the human CD8a hinge
region (amino acids 138 to 182), CD28 transmembrane
and cytoplasmic domains (amino acids 153 to 220) and the
T-cell receptor CD3ζ chain (amino acids 52 to 164). Briefly,
in the first round of conventional PCRs using the Platinum
Taq DNA Polymerase High Fidelity kit (Invitrogen), CD8a
hinge region, CD28 and CD3ζ were amplified using the pri-
mer pairs CF and CR, DF and DR, and EF and ER, respect-
ively. The human CD8a leader peptide fragment was
synthesized (Takara Bio, Otsu, Japan) and then fused to
chA21 scFv using the primers AF and BR by OE-PCR. A
fragment encoding the CD8a hinge region was fused to
CD28 using primers CF and DR, and then the PCR product
(CD8a hinge +CD28) was fused to CD3z using primers CF
and ER. These two PCR products were combined, and the
full-length construct was generated using the AF and ER
primers. The DNA encoding the full-length construct was
ligated into the pSin lentiviral backbone (Addgene, Cambridge,
MA, USA) to create the pSin-chA21-28Z plasmid.
Lentivirus production and transduction of peripheral
blood mononuclear cells
Lentiviral particles were produced by transfecting 293 T
cells with the lentiviral expression plasmid and the
packaging plasmids. Briefly, 293 T cells were seeded
into a 75-cm2 flask, and Lipofectamine 2000 (Invitrogen)
was used as the transfection reagent at a ratio of 1 μg of
DNA to 1.5 μl of Lipofectamine, according to the manu-
facturer’s instructions. The following amounts of DNA
per 75-cm2 flask were used: 11 μg of chA21-28z transgene
plasmid, 3.5 μg of vesicular stomatitis virus G glycoprotein
envelope encoding pMD.G plasmid, 5 μg of packaging
pMDLg/p plasmid and 2.5 μg of Rev-expressing plasmid.
Two collections of viral supernatant were made 24 and
48 hours after transfection. After filtering the collections
through a 0.45-μm filter (EMD Millipore, Billerica, MA,
USA), a 0.75-ml aliquot of viral vector was frozen at −80°C
for later use.
PBMCs were isolated by Ficoll density gradient centrifu-
gation and activated with anti-CD3/CD28 beads (Invitro-
gen). Twenty-four hours after activation, PBMCs were
transduced with lentiviral vectors at a multiplicity of infec-
tion of 5 and expanded for approximately 2 weeks.
Fluorescence-activated cell sorting analysis
Anti-human CD45, CD3, CD4 and CD8 antibodies were
purchased from BioLegend (San Diego, CA, USA). Cell
Table 1 Primer sequences for HER2 chimeric antigen receptor construct
Gene names Primer names Primer sequences (5′-3′)
CD8a leader AF gcggaattcatggccttaccagtgaccgccttgctcctgccg (EcoRI)
Her2scFv BF tgctccacgccgccaggccgagatctgacattgtgctgacccaaac
BR tgacgagacggtgactgaggttcc
CD8a hinge CF cctcagtcaccgtctcgtcaaccacgacgccagcgccgcg
CR atcacaggcgaagtccagccccc




Note: EcoR1 and Sal1 restriction enzyme sites are italicized.
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isothiocyanate anti-HER2 antibody (clone 24D2; BioLe-
gend). Matched isotype control antibodies were used in
all analyses. HER2-specific CAR expression was detected
by R-Phycoerythrin-AffiniPure F(ab′)2 antigen-binding
fragment goat anti-mouse antibody (Jackson Immuno-
Research Laboratories, West Grove, PA, USA). Flow cy-
tometric data were analyzed using FlowJo version 7.2.5
software (TreeStar, Ashland, OR, USA).
Enzyme-linked immunosorbent assay
A cytokine release assay was performed by coculture of
105 T cells with 105 target cells per well in triplicate in
96-well flat-bottom plates in a 200-μl volume of complete
medium. In addition, wells containing T cells alone were
used as negative controls. The plates were incubated at
37°C. For antigen-specific assays, triplicate wells of Nunc
MaxiSorp MicroWell plates (BioLegend) were coated
with 5 μg/ml HER2-Fc chimeric protein (R&D Systems,
Minneapolis, MN, USA) or CD19-Fc chimeric protein
(SPEED BioSystems, Rockville, MD, USA) in 200 μl of
phosphate-buffered saline (PBS) overnight at 4°C. After
three washings with PBS, 105 nontransduced (NT) or
CAR-transduced T cells were then added, followed by
incubation at 37°C. After about 24 hours, cell-free super-
natants were assayed for the presence of interferon γ
(IFN-γ) or IL-2 with an enzyme-linked immunosorbent
assay kit (BioLegend).
Chromium-51 release assay
The ability of the T cells to lyse tumor target cells was
measured using a standard 4-hour chromium-51 (51Cr)
release assay. Briefly, 1 × 106 target cells were labeled
with 0.1 mCi (3.7 MBq) 51Cr and mixed with decreasing
numbers of effector cells at effector-to-target ratios of
30:1, 10:1, 3:1 and 1:1. After 4-hour incubation, harvested
supernatants were counted using a WIZARD2 Automatic
Gamma Counter (PerkinElmer, Waltham, MA, USA).
Target cells incubated in complete medium alone or in 1%Triton X-100 were used to determine spontaneous and
maximal 51Cr release, respectively. The mean percentage
of specific lysis of triplicate wells was calculated according
to the following formula: Specific lysis (%) = [(Specific re-
lease − Spontaneous release)/(Maximal release − Spontan-
eous release)] × 100.
Xenograft model of breast cancer
The animal studies were approved by the Animal Ethics
Committee of Shandong University. Nonobese diabetic/
severe combined immunodeficient (NOD/SCID) mice
were purchased from Beijing HFK Bioscience Co (Beijing,
China). Eight- to twelve-week-old mice were bred and
maintained under pathogen-free conditions in-house ac-
cording to protocols approved by the Shandong University
Institutional Animal Care and Use Committee. Female
NOD/SCID mice were inoculated subcutaneously with
2 × 106 SKBR3 cells on the flank on day 0. Sixty percent of
mice developed solid tumors, and five tumor-bearing mice
per group were randomized before treatment. After tu-
mors became palpable, human PBMCs were activated and
transduced as described above. After 2 weeks of expan-
sion, when tumor burden was approximately 300 mm3,
2 × 107 T cells (70% CAR+) or NT T cells were injected
intravenously into the mice, and this was repeated 7 days
later. Tumor dimensions were measured with calipers,
and tumor volumes were calculated using the following
formula: V =½ × (length × width2), where length is the
greatest longitudinal diameter and width is the greatest
transverse diameter.
Immunohistochemistry
The mice were killed by carbon dioxide (CO2) inhalation,
and the tumors were removed and frozen in Tissue-Tek
O.C.T. compound at −80°C. A standard streptavidin horse-
radish immunoperoxidase method was used for human
CD3 staining as described previously [16]. Briefly, 7-μm
cryosections were fixed in cold acetone for 5 minutes at
4°C and blocked with a peroxidase blocking system for
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munostaining was carried out with an initial 30-minute
incubation with 10% normal goat serum at room tempe-
rature (RT), primary rabbit anti-human CD3 for T cells
(RM-9107; Thermo Scientific, Waltham, MA, USA) at
1:100 dilution at RT for 45 minutes, secondary biotinyl-
ated goat anti-rabbit antibody at 1:200 dilution at RT for
30 minutes and streptavidin-biotinylated horseradish per-
oxidase complex reagent (Dako) at RT for 30 minutes,
followed by washing three times for 5 minutes each after
each incubation. Sections were then exposed to DAB+
chromogen (Dako) for 5 minutes at RT, counterstained
with hematoxylin, dehydrated, cleared and mounted.
Statistical analysis
All data are reported as means ± SD. Data were analyzed
using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego, CA, USA). Statistical
analysis was performed by analysis of variance for the
tumor burden (tumor volume). Student’s t-test was used
to evaluate differences in cytokine secretion and specific
cytolysis. P-values <0.05 were considered significant.A






Figure 1 Schematic diagram of the chA21-28z chimeric antigen recep
extension PCR. (A) Diagram of the HER2-specific chimeric antigen receptor
(scFv) linked to CD28 and CD3z signaling moieties. (B) Agarose gel electroph
(C) Lane 1, A21 scFv; lane 2, CD8a leader + chA21 scFv; lane 3, CD8a hinge; la
lane 7, CD8a hinge + CD28 (TM + ICD) + CD3z. (D) Lane 1, chA21-28z CAR:CD
pSin lentiviral vector; lane 3, pSin-chA21-28z CAR plasmid.Results
Construction of HER2-specific chimeric receptor
The humanized HER2-specific scFv chA21 was selected on
the basis of its high binding affinity for HER2 (KD = 11 nm)
[17]. The affinity of chA21 scFv in the CAR construct is
not known. HER2-specific CAR, consisting of chA21 scFv
linked to CD28 and CD3z signaling moieties, was con-
structed and cloned into a lentiviral vector and named
chA21-28z CAR (Figure 1A). The PCR products were
constructed by fusion of independent fragments using an
OE-PCR technique (Figures 1B, 1C and 1D). Briefly, in the
first round of PCRs, the chA21 scFv (Figure 1B, lane 2) was
amplified from PEE14-chA21 plasmid (Figure 1B, lane 1).
The CD8a hinge region, CD28 and CD3ζ (Figure 1C, lanes
3, 4 and 6) were amplified from T-cell cDNA using conven-
tional PCR conditions. Fragments generated by OE-PCR
were also separated by electrophoresis to determine
PCR product size. Figure 1C, lane 5: CD8a hinge CD28
(TM + ICD), lane 7: CD8a hinge CD28 (TM + ICD)
CD3z; Figure 1D, lane 1: CD8a leader chA21 scFv CD8a
hinge CD28 (TM + ICD) CD3z, lane 2: pSin lentiviral










tor construct and chimeric gene products generated by overlap
(CAR), consisting of a humanized chA21 single-chain variable fragment
oresis of PCR products. Lane 1, PEE14-chA21 plasmid; lane 2, chA21 scFv.
ne 4, CD28TM+ ICD; lane 5, CD8a hinge + CD28 (TM + ICD); lane 6, CD3z;
8a leader + chA21 scFv + CD8a hinge + CD28 (TM + ICD) + CD3z; lane 2,
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and the final plasmid was sequenced to confirm its
identity.
Expanded chimeric antigen receptor T cells express a
central memory phenotype
Anti-CD3/CD28 bead-activated PBMCs from three
healthy donors were transduced with HER2 CAR lentiviral
vectors. After 14 days of culture, as shown in Additional
file 2: Figure S2A and Figure 2A, more than 95% of
the total cultured NT or CAR-transduced PBMCs were



























Figure 2 The chA21-28z chimeric antigen receptor T cells cultured in
markers CD45RO and CD62L. (A) CD3+ T cells were the predominant ce
mononuclear cells (PBMCs) cultured in vitro from three different donors co
antigen receptor (CAR) expression was detected by staining T cells with F(a
CD8+ cells expressed HER2-specific CAR. (C) The T lymphocytes cultured in
ation markers CD45RO and CD62L. The phenotypes of the cultured T cellsmost T cells expressed the CD8+ phenotype (Additional
file 2: Figure S2B and Figure 2B). Activated CD8+ T cells
generally proliferate faster than activated CD4+ T cells,
and thus activation can promote a relative enrichment of
CD8+ T cells in culture, which may explain the CD8+
phenotype of T cells. On average, approximately 70% of
CD3+ T cells expressed HER2 CAR, which we determined
by fluorescence-activated cell sorting (FACS) analysis.
Both CD4+ and CD8+ Tcells were transduced (Figure 2B).
CD3+ NT and CAR T cells were further analyzed using
the differentiation markers CD45RO and CD62L. Consist-
ently, in the three donors tested, the central memory T4 CD8
Day 14












vitro exhibit distinct populations defined by the differentiation
ll population after 2 weeks of expansion. On day 14, peripheral blood
ntained more that 95% CD3 + CD45+ T cells. (B) HER2-specific chimeric
b′)2 antigen-binding fragment anti-mouse antibody. Both CD4+ and
vitro were gated on CD3+ T cells and analyzed using the differenti-
from representative donors at days 0 and 14 are shown in dot plots.
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plentiful at day 14, following transduction and in vitro cul-
ture (Additional file 2: Figure S2C and Figure 2C). Yang
et al. [18] demonstrated that the phenotype of Tcm cells
may be the most appropriate type for adoptive cell therapy.
HER2 chimeric antigen receptor–modified T cells were
specifically reactive to HER2+ tumor cell lines
HER2 expression of a panel of tumor cell lines was
examined by FACS and cell staining with an anti-HER2
antibody. The results show that HER2 expression was
easily detected, not only for breast cancer cell lines SKBR3,
MCF-7 and T47D but also for the ovarian cancer cell lines
SKOV3, OVCAR3, A2780 and A1847. In addition, HER2
expression could be detected in a triple-negative breast
cancer cell line, MDA-MB-231 (Figure 3A).
To test whether T cells expressing chA21-28z CAR
were capable of specifically recognizing tumor lines ex-
pressing HER2, we coincubated CAR T cells with a panel
of tumor cell lines and determined the amount of secretedFigure 3 Transduced chA21-28z chimeric antigen receptor T cells sec
(A) Breast and ovarian cancer cell lines were stained with a monoclonal an
HER2 expression was evident in the majority of cell lines after staining with
with control antibody (dashed lines). MDA-MB-468 and TC-1 were used as
interleukin 2 (IL-2) secretion by chA21-28z chimeric antigen receptor (CAR)
overnight incubation with HER2+ cancer cell lines. Mean IFN-γ and IL-2 concytokines IFN-γ and IL-2. chA21-28z CAR T cells recog-
nized all of the HER2+ tumor lines and secreted IFN-γ
and IL-2 at high levels. Very low levels of IFN-γ and IL-2
were observed when cocultured with the MDA-MB-468
and TC-1 cell lines, which we determined were negative
for HER2 expression by FACS analysis. Only minimal
IFN-γ and IL-2 production was detected when NT T
cells were cocultured with HER2+ or HER2− cell lines
(Figures 3B and 3C). To find out whether the recognition
of HER2 by CAR T cells was antigen-specific, we tested
whether coated HER2-Fc protein could activate CAR T
cells. As shown in Additional file 3: Figure S3C, when in-
cubated with HER2-Fc protein, but not CD19-Fc protein,
HER2 CAR T cells were activated and released IFN-γ at a
high level.
Next, we evaluated the ability of CAR T cells to medi-
ate lysis of HER2+ tumor cells in a 4-hour 51Cr release
assay. CAR T cells lysed HER2+ SKOV3, SKBR3 and
T47D cells (Figure 4A), but not HER2− MDA-MB468
and TC-1 cells. Lysis of these tumor cells was dependentrete interferon γ and interleukin 2 in response to tumor cells.
tibody specific for the HER2 antigen and analyzed by flow cytometry.
an anti-HER2 monoclonal antibody (thick lines) compared to staining
negative controls. (B) and (C) Antigen-specific interferon γ (IFN-γ) and
–transduced T cells, but not nontransduced (NT) T cells, following





Figure 4 Specific lysis by chA21-28z chimeric antigen receptor T cells in vitro. (A) Antigen-specific killing of HER2+ tumor cells by chA21-28z
chimeric antigen receptor (CAR) T cells was determined using a 4-hour chromium-51 release assay at the indicated effector-to-target (E/T) ratio.
Nontransduced (NT) T cells and HER2− tumor cells served as controls. (B) NT or chA21-28z CAR T cells were seeded into cultures of SKOV3 cells
expressing HER2. After about 24 hours in coculture, formation of T-cell clusters and elimination of the SKOV3 monolayer were visible.
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observed. In addition, we seeded NT or chA21-28z CAR T
cells into cultures of SKOV3 cells expressing HER2. After
24 hours of T-cell seeding, formation of T-cell clusters
and elimination of the SKOV3 monolayer were visible
(Figure 4B). These results indicate that HER2-specific T
cells recognize and kill HER2+ cells in a HER2-specific
manner.
Antitumor responses by HER2 chimeric antigen receptor
T cells in vivo
Having determined the antitumor activity of chA21-28z
CAR T cells in vitro, we next sought to discover their anti-
tumor ability in tumor-bearing mice. We compared the
potency of CAR T cells to that of NT T cells in terms of
tumor volume in a xenograft model. A total of 2 × 106
SKBR3 cells were subcutaneously injected into NOD/SCID
mice, and tumor volume reached 300 mm3 after about
7 weeks. Treatment was performed weekly for 2 weeks,
and tumor growth was monitored. chA21-28z CAR T cells
elicited stronger antitumor responses than the responses
in the control mice treated with NT T cells (P = 0.00012)
(Figures 5A and 5B). The average tumor weight of the
control group was 0.79 ± 0.03 g, and that of the CAR T
cell–treated group was 0.16 ± 0.02 g (P = 0.0023) (Figure 5C)
at day 92 after inoculation of tumor cells, indicating that
CAR T cells significantly inhibited tumor growth.The infiltration of tumor-reactive T cells into tumors
was highly correlated with tumor regression. Immuno-
histochemical analysis revealed robust accumulation of
human CD3+ T cells in regressing SKBR3 lesions 7 weeks
after intravenous T-cell injection, although few CD3+ T
cells were detected in tumors that received NT T-cell
injections (Figure 5D).
Discussion
Our goal in this study was to construct and evaluate a
novel anti-HER2 chA21 scFv-based CAR. CARs are re-
combinant receptors that couple antigen-specific targeting
of an extracellular antibody, scFv, with intracellular T-cell
signaling domains for the generation of antigen-redirected
T cells for therapy. We utilized an OE-PCR technique to
generate a linearized, HER2-specific CAR that contains a
CD28 costimulatory signaling domain. OE-PCR provides
a rapid, cost-effective means of creating chimeric recep-
tors without the need for available enzyme recognition
sequences [19,20]. Furthermore, PCR-based methods
have become increasingly reliable with the introduction
of high-fidelity DNA polymerases, thus limiting the num-
ber of unwanted mutations in the final construct [19-21].
This method has proven to be useful for the construction
of CARs containing various costimulatory signaling do-
mains, and these CARs can simply be cloned into a stand-











Figure 5 chA21-28z chimeric antigen receptor T cells inhibit tumor growth in vivo. (A) Two million SKBR3 tumor cells were injected
subcutaneously into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, followed by intravenous treatment with T cells
beginning on either day 40 or day 47 after tumor inoculation. Tumors regressed in response to injections of chA21-28z chimeric antigen receptor
(CAR) T cells (triangles). Tumors grew progressively in mice (squares) that received nontransduced (NT) T-cell injections. HER2 CAR T cells inhibited
tumor growth to a significantly greater extent compared to the control group (P = 0.00012). (B) SKBR tumors were dissected, and photographs of
four representative samples are shown. (C) Graphed tumor weight data. Values are expressed as mean ± SEM. (D) SKBR3 tumors were collected
from killed mice and stained for human CD3 expression (brown). Representative sections are shown at 100× original magnification.
Sun et al. Breast Cancer Research 2014, 16:R61 Page 8 of 10
http://breast-cancer-research.com/content/16/3/R61Various costimulatory domains have been tested in
CAR constructs, including CD28, 41BB, CD27, ICOS
and OX40 [11,22-24]. Notably, CD28 costimulation aug-
ments antiapoptotic Bcl-XL expression [25], increases
IL-2-independent proliferation, enhances the resistance
of CAR T cells to T regulatory cells [26] and is the costi-
mulatory domain choice for most CARs. In clinical stud-
ies, antitumor activity and the persistence of CAR T cells
can be enhanced by adding a CD28 costimulatory domain
[27]. Therefore, in our study, we added the signaling do-
main of CD28 to the cytoplasmic domain of the chA21
scFv CAR domain to achieve full T-cell activation.
chA21 scFv was derived from chA21 mAb, which may
represent another group of anti-ErbB2 antibody. chA21
mAb recognizes epitopes that are located mainly in sub-
domain I and apart from the functional sites for HER2
receptor dimerization, whereas trastuzumab (4D5) binds
to the juxtamembrane region in subdomain IV [28]. Im-
portantly, researchers in previous studies [29-31] have
demonstrated that the chA21 mAb can inhibit growth
and induce apoptosis of the human ovarian cancer cell
line SKOV3 by regulating the balance between Bax and
Bcl-2, suggesting that chA21 mAb might be a promisingnew candidate in the treatment of HER2-overexpressing
cancers.
In this study, we found that human T cells expressing
chA21 scFv-28z-based CARs lysed HER2+ breast and
ovarian cancer cells with high efficiency. CAR T cells
recognized and killed tumor cells in an MHC-independent
manner, so that target cell recognition by CAR T cells was
unaffected by downregulation of human leukocyte antigen
class I molecules and defective antigen processing. Besides
tumor cell killing, cytokines production of CAR T cells
suggest their activation and sustained antitumor activity.
chA21-28z CAR T cells were capable of producing greater
amounts of IFN-γ and IL-2 compared to NT T cells.
IFN-γ produced by cytotoxic T cells is critical for exerting
immune surveillance of tumors, which can directly inhibit
proliferation and induce apoptosis of some malignancies
in vivo and in vitro through elusive mechanisms [32]. IL-2
is pivotal for the proliferation and differentiation of T cells
to become effector T cells. Moreover, two systemic injec-
tions of chA21-28z T cells against subcutaneous tumors
led to dramatic tumor regression in mice. This type of
model is generally accepted to be a test of therapy more
stringent than other models that involve injection of
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was attainable by systemic T-cell delivery, showing the cap-
acity of transferred T cells to circulate, home to the tumor
and perform antitumor functions. In addition, humanized
chA21 scFv-based CAR T cells may greatly reduce their
immunogenic potential in vivo. However, even fully human
antibodies may lead to the production of human antihu-
man antibodies, and only use in a clinical trial will prove
conclusively whether they are nonimmunogenic.
HER2 CAR T-cell therapies have been tested in various
cancer models in mice, including breast cancer [33],
ovarian cancer [34], medulloblastoma [35], glioblastoma
[36] and osteosarcoma [37]. Zhao et al. [33] reported that
trastuzumab-based 4D5 CAR T cells reacted against a
panel of tumor cells of different origin that expressed even
low levels of HER2, as well as multiple normal cells. In a
clinical setting, transfer of high numbers of 4D5 CAR T
cells encompassing CD28 and CD137 costimulatory do-
mains following lymphodepletion was reported to result
in severe toxicity, including cytokine storm, respiratory
distress and ultimately patient death due to the CAR T
cells’ response against lung epithelial cells expressing low
levels of HER2 [38]. In the future, we will compare the
antitumor activity of adoptive HER2 CAR T-cell therapy
with passive immunotherapy with trastuzumab. Import-
antly, incorporating a suicide gene, such as the inducible
caspase 9 suicide gene system, within engineered CAR T
cells would provide a safety control for clinical application
[39]. Moreover, injections of transient CAR-expressing T
cells electroporated with mRNAs appear to be safe, and
the toxicity would be expected to abate rapidly [40].
Conclusions
Collectively, we constructed an HER2-specific CARs using
a novel, humanized HER2 scFv. We demonstrate for the
first time, to the best of our knowledge, that a novel
chA21 scFv-based, HER2-specific CAR Tcell not only rec-
ognized and killed HER2+ breast and ovarian cancer cells
ex vivo but also induced regression of experimental breast
cancer in vivo. Hence, the adoptive transfer of HER2-
redirected T cells may be a viable immunotherapeutic
approach for treating HER2-expressing cancers.
Additional files
Additional file 1: Figure S1. Nucleotide and amino acid sequences of
chA21-28z CAR construct. 1 to 6 bp: EcoRI; 7 to 69 bp: CD8a leader; 70 to
837 bp: chA21 scFv; 838 to 972 bp: CD8a hinge; 973 to 1,059 bp: CD28
transmembrane; 1,060 to 1,176 bp: CD28 intracellular domain; 1,177 to
1,512 bp: TCR-CD3z intracellular domain; 1,513 to 1,515 bp: Stop codon;
1,516 to 1,521: SalI.
Additional file 2: Figure S2. The phenotype of NT T cells cultured
in vitro. (A) CD3+ T cells were the predominant cell population after
2 weeks of expansion. On day 14, PBMCs from three different donors
cultured in vitro contained more that 95% CD3 + CD45+ T cells. (B) MostT cells expressed the CD8+ phenotype. (C) The NT T lymphocytes cultured
in vitro were gated on CD3+ T cells and analyzed using differentiated
markers CD45RO and CD62L. The phenotype of the cultured T cells from a
representative donor at days 0 and 14 is shown in dot plots.
Additional file 3: Figure S3. The recognition of HER2 by CAR T cells
was antigen-specific. Triplicate wells of Nunc MaxiSorp MicroWell plates
were coated with 5 μg/ml HER2-Fc chimeric protein or CD19-Fc chimeric
protein in 200 μl of PBS overnight at 4°C. After three washings with PBS, 105
NT or CAR T cells were added, followed by incubation at 37°C. After about
24 hours, cell-free supernatants were assayed for the presence of IFN-γ.
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